drugset
drugset / Trial / NCT01192230

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

NCT01192230 ↗

Phase 2 Unknown 30 enrolled Fudan University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the efficacy and safety of endostatin combined with Docetaxel in advanced Non-Small-Cell Lung Carcinoma (NSCLC) patients failure to first-line or second-line chemotherapy.

Timeline

Start
2009-06
Primary completion
2011-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 —
Subject Endostatins Protein / enzyme biologic 7.5 mg/m2 —

Indications

non-small cell lung carcinoma